# US Infertility Market

> US Infertility Market Research Report: Size, Share, Trend Analysis By Sex (Males, Females, Unexplained), By Diagnosis (Men Diagnostic Tests, Women Diagnostic Tests, General Diagnostic Test), By Drugs (Clomiphene Citrate, Letrozole, Serophene, Hormone Treatment, Others) and By Technology (Assisted Reproductive Technology, Intrauterine Insemination, Surgery) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 0.1%
- **2024:** $ 534.26 Million
- **2025:** $ 533.73 Million
- **2035:** $ 528.67 Million
- **Key Players:** CooperSurgical (US), Merck KGaA (DE), Ferring Pharmaceuticals (CH), Irvine Scientific (US), Vitrolife(SE), Reproductive Health Technologies (US), OvaScience (US), Genea (AU)

**Report ID:** MRFR/MED/16432-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-infertility-market-17960

---

## Market Summary

## **US Infertility Market Overview**

As per MRFR analysis, the US Infertility Market Size was estimated at 379.72 (USD Million) in 2023. The US Infertility Market Industry is expected to grow from 430 (USD Million) in 2024 to 1,611 (USD Million) by 2035. The US Infertility Market CAGR (growth rate) is expected to be around 12.758% during the forecast period (2025 - 2035).

### **Key US Infertility Market Trends Highlighted**

The US Infertility Market is experiencing significant trends driven primarily by rising infertility rates and increased awareness of reproductive health. Factors such as lifestyle changes, delayed childbirth, and conditions like polycystic ovary syndrome (PCOS) are contributing to a growing number of couples seeking infertility treatments. The US healthcare system increasingly recognizes the importance of fertility preservation, which aligns with the rising trend of women prioritizing careers over early childbearing, leading to a greater demand for assisted reproductive technologies (ART). Opportunities to be explored include the expansion of telehealth services within fertility treatment.

The COVID-19 pandemic has accelerated the adoption of virtual consultations, making it easier for individuals to access fertility specialists without geographic constraints. There is also an emerging market for fertility preservation in younger demographics, such as women looking to freeze their eggs for future use, reflecting a shift in societal norms around family planning. The incorporation of advanced technologies such as Artificial Intelligence and machine learning in IVF procedures showcases the potential for improved treatment outcomes and patient experiences.

Recent trends also indicate a focus on personalized medicine in the infertility sector, with clinics starting to offer tailored treatment plans based on genetic testing and individual health profiles.

Furthermore, increasing advocacy for insurance coverage for infertility treatment may lead to broader access, making treatments more affordable for a larger segment of the population. The US market is poised for growth as it simultaneously addresses the emotional and financial challenges faced by individuals and couples trying to conceive, contributing to a more supportive environment for fertility treatments.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **US Infertility Market Drivers**

#### **Increasing Awareness and Acceptance of Infertility Treatments**

The US Infertility Market Industry is witnessing a significant increase in awareness and acceptance of infertility treatments. Education campaigns and initiatives by organizations such as the American Society for Reproductive Medicine (ASRM) have contributed to a greater awareness about the options available for couples facing infertility. According to a report from the Centers for Disease Control and Prevention (CDC), approximately 6.1 million women in the United States are affected by infertility, which translates to nearly 10% of women aged 15 to 44. This statistic emphasizes the growing need for effective treatments and therapies in the US Infertility Market.

The rise in the number of fertility clinics offering advanced reproductive technologies, including in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), has resulted in increased accessibility to these services, thereby catalyzing market growth. Furthermore, there is a notable trend among millennials and Generation Z being more open about discussing reproductive health issues, making them more likely to seek treatment, thus positively impacting market prospects.

#### **Technological Advancements in Fertility Treatments**

Rapid advancements in reproductive technology are a major driver for the US Infertility Market Industry. Technologies such as preimplantation genetic diagnosis (PGD) and the development of artificial intelligence in treatment procedures have shown promising results in increasing success rates of fertility treatments. The use of time-lapse imaging in embryo culture has improved the efficiency of selecting viable embryos for transfer. Reports indicate that between 2015 and 2020, the success rate of IVF procedures increased by 5% annually, thanks to these modern technologies.

Organizations like the Society for Assisted Reproductive Technology (SART) play an essential role in tracking and reporting these advancements, which not only enhance treatment success but also build trust in the market, encouraging more couples to pursue interventions.

#### **Rising Maternal Age**

The demographic trend of women choosing to have children at a later age is significantly influencing the US Infertility Market Industry. The average age of first-time mothers in the United States has been rising, reaching approximately 26.9 years in 2020, according to the National Center for Health Statistics. As women age, the likelihood of fertility issues increases, leading to a greater demand for infertility treatments. The American College of Obstetricians and Gynecologists (ACOG) states that fertility begins to decrease in women from their early 30s, which further highlights the urgency for reproductive health services among older couples.

This trend directly correlates to an increased market size as more individuals seek assistance to conceive.

#### **Government Support and Funding for Infertility Treatments**

Government policies aimed at supporting reproductive health are bolstering the US Infertility Market Industry. The passage of the Affordable Care Act (ACA) has subjected many health insurance plans to cover infertility treatments, making them more affordable for a larger segment of the population. According to the National Conference of State Legislatures, as of 2022, at least 15 states have laws mandating insurance coverage for infertility treatments. This legislative environment is conducive to higher utilization rates of fertility services among insured individuals.

Additionally, federal funding for fertility clinics has been expanded, facilitating Research and Development initiatives that continue to improve treatment methodologies, thus promoting market expansion.

### **US Infertility Market Segment Insights**

#### **Infertility Market Sex Insights**

The US Infertility Market, with a notable focus on the Sex segment, plays a critical role in addressing reproductive health challenges faced by individuals and couples across the United States. This market has experienced substantial growth, characterized by increasing awareness about infertility issues and advancements in reproductive technologies. Both male and female infertility encompass unique factors that contribute to challenges in conception, with male infertility often associated with lifestyle choices, environmental factors, and health conditions affecting sperm quality and count.

Conversely, female infertility can arise from a multitude of causes, including age-related factors, hormonal imbalances, and medical conditions such as polycystic ovary syndrome (PCOS) or endometriosis. The segment also includes unexplained infertility, which becomes particularly significant as it represents a category of patients whose fertility challenges remain unidentified despite comprehensive testing. The demand for fertility services has surged, propelled by changing societal attitudes toward family planning and a growing commitment to reproductive health. Factors such as delayed childbearing, increasing rates of obesity, and more women pursuing higher education and careers later in life contribute to the complexity of infertility.

Moreover, the ongoing research into reproductive health, including studies on genetics and reproductive technologies, continues to illuminate potential causes and treatment options, thus enhancing the landscape of the US Infertility Market. With the increasing adoption of assisted reproductive technologies, including in vitro fertilization (IVF), intrauterine insemination (IUI), and egg freezing, the landscape for addressing infertility is becoming increasingly sophisticated. Additionally, the rising prevalence of health issues related to reproductive health among both genders demonstrates the urgency for comprehensive solutions and personalized treatment approaches.

By recognizing the distinct challenges posed by male, female, and unexplained infertility, stakeholders in the US Infertility Market can better tailor services and foster innovations in reproductive health, ultimately improving patient outcomes and experiences. This intricate interplay among factors influencing infertility underscores the importance of continued investment in research, education, and access to care, enabling a proactive approach to supporting individuals and couples in their family-building journeys. The growing incorporation of mental health support into infertility care is also gaining traction, acknowledging the psychological impact that infertility can have on individuals and couples.

As the US Infertility Market evolves, it will likely see a more integrated model that encompasses both medical and emotional support, catering to the comprehensive needs of patients navigating this journey.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

#### **Infertility Market Diagnosis Insights**

The Diagnosis segment of the US Infertility Market is a critical component responsible for identifying underlying issues affecting fertility. As the market continues to grow, diagnostic testing for both men and women remains vital for determining the most effective treatment protocols. Men's diagnostic tests typically assess sperm quality and function, which play a significant role in male infertility cases, while women's diagnostic tests focus on hormonal levels and reproductive health, addressing issues such as ovulation disorders or blockages in the fallopian tubes.

General diagnostic tests serve as an overview for assessing both partners, ensuring comprehensive evaluations in infertility cases, leading to more personalized treatments. In the US, the rising awareness about reproductive health, coupled with advancements in testing technologies, propels the demand for accurate diagnostics. Additionally, challenges such as increasing infertility rates and fluctuating lifestyle choices contribute to the urgency for effective diagnostic solutions. Hence, the Diagnosis segment not only plays a crucial role in treatment planning but also holds the potential for continuous innovation and growth in the US Infertility Market.

The focus on early diagnosis is expected to drive more individuals and couples to seek medical assistance, leading to improved success rates in fertility treatments.

#### **Infertility Market Drugs Insights**

The US Infertility Market, particularly within the Drugs segment, plays a crucial role in addressing infertility challenges faced by couples across the country. Leading medications such as Clomiphene Citrate and Letrozole are pivotal in stimulating ovarian function, aiding in ovulation induction for women experiencing difficulty conceiving. Serophene, a well-known treatment, is significant in enhancing fertility rates, thus contributing to the growing demand in the market. Hormone Treatments remain essential in correcting hormonal imbalances that can hinder fertility, making them a vital part of comprehensive infertility therapies.

The focus on these treatments is driven by an increasing awareness of reproductive health issues among the US population, alongside rising incidences of infertility caused by factors such as delayed pregnancies and lifestyle choices. The landscape of the US Infertility Market continues to evolve with innovative drug formulations and treatment protocols, offering new hope for many. Overall, the market growth in the Drugs segment is fueled by ongoing Research and Development efforts, educational initiatives aimed at demystifying infertility, and a continuous push for accessibility to these crucial treatments.

#### **Infertility Market Technology Insights**

The Technology segment within the US Infertility Market showcases a marked expansion as it adapts to meet the growing demand for advanced reproductive solutions. Assisted Reproductive Technology (ART) plays a crucial role, incorporating sophisticated techniques that help couples achieve pregnancy, demonstrating significant effectiveness and adoption rates. Intrauterine Insemination (IUI), another key approach, offers a less invasive option, making it appealing for various patients seeking assistance with conception. [Surgery](../../../reports/corneal-surgery-devices-market-913) remains a vital component, addressing anatomical issues such as blockages or fibroids that directly impact fertility.

With an increasing awareness of infertility challenges, coupled with technological advancements, the market is witnessing a shift towards more innovative methods. As healthcare policies in the US evolve, and as more individuals seek options for family planning, the emphasis on these technologies is likely to grow, influencing the US Infertility Market revenue positively. This segment is not only important for treatment effectiveness but also for enhancing patient experience, thereby driving market growth and interest in fertility solutions across the nation.

Moreover, ongoing Research and Development efforts aim to fine-tune these techniques, ensuring that they evolve to better meet patient needs while maintaining high standards of safety and efficacy.

### **US Infertility Market Key Players and Competitive Insights**

The US Infertility Market is characterized by a diverse range of services and solutions aimed at addressing the challenges faced by couples and individuals seeking to conceive. This market has seen significant growth in recent years due to increasing awareness about fertility treatments, advancements in reproductive technologies, and the rising prevalence of infertility issues attributed to various factors including lifestyle changes and medical conditions.

The competitive landscape is marked by a combination of established clinics, specialized fertility centers, and innovative biotech companies that are continually vying for market share by enhancing service offerings, expanding their geographic reach, and improving patient experiences through personalized care and cutting-edge technologies.

Boston IVF boasts a strong presence in the US Infertility Market, recognized for its high success rates and comprehensive range of fertility services. As a pioneer in reproductive medicine, Boston IVF has established a solid reputation through its commitment to patient outcomes, utilizing advanced techniques such as in vitro fertilization and intracytoplasmic sperm injection. The clinic prides itself on its team of highly skilled specialists and its patient-centric approach, which emphasizes individualized treatment plans tailored to the unique needs of each patient.

This dedication to excellence not only strengthens its market position but also fosters patient loyalty, as many couples trust Boston IVF with their fertility journeys. Its well-maintained facilities equipped with state-of-the-art technologies further enhance its appeal, thereby solidifying Boston IVF's role as a leader in the competitive arena of infertility solutions.

Evoque is another significant player in the US Infertility Market, recognized for its innovative approach to fertility treatments. The company specializes in providing advanced reproductive technologies, including genetic testing and embryo selection services, aimed at maximizing the chances of successful conception. Evoque thrives on its ability to combine research with practical applications, offering cutting-edge solutions that cater to the evolving needs of fertility patients. The company's focus on merging science with patient care translates into a range of key services that greatly enhance its market presence.

Evoque has also engaged in strategic partnerships and collaborations that have strengthened its market position and expanded its service capabilities. Through a series of targeted mergers and acquisitions, Evoque has enhanced its operational efficiencies and broadened its reach, thereby consolidating its strengths in the highly competitive US Infertility Market. Its emphasis on innovation ensures that Evoque remains at the forefront of advancements in fertility treatment, making it a notable contender in the landscape of reproductive health and wellness.

### **Key Companies in the US Infertility Market Include**

### **US Infertility Market Industry Developments**

The US Infertility Market has recently seen significant developments, with a focus on advancements in reproductive technologies and treatments. Companies such as Boston IVF and HRC Fertility are at the forefront of innovation, utilizing cutting-edge techniques to enhance success rates in assisted reproductive technologies. In August 2023, Merck KGaA announced a partnership with UCSF Center for Reproductive Health aimed at increasing access to fertility preservation services. Additionally, Evoque is focusing on expanding its genetic screening capabilities, which is essential for improving patient outcomes.

The market is also witnessing growth due to rising infertility rates, influenced by lifestyle factors and increased awareness around reproductive health. In terms of mergers and acquisitions, in June 2023, Ferring Pharmaceuticals acquired a subsidiary of Vitrolife, further consolidating its position within the US market. The overall valuation of the US Infertility Market is projected to grow substantially, driven by advancements in technology and increasing demand for effective infertility treatments. Collaborations between companies such as AbbVie and Reproductive Health Technology highlight the ongoing efforts to enhance research and development in this field.

### **US Infertility Market Segmentation Insights**

#### **Infertility Market Sex Outlook**

#### **Infertility Market Diagnosis Outlook**

#### **Infertility Market Drugs Outlook**

#### **Infertility Market Technology Outlook**

## Market Drivers

### Rising Infertility Rates

The infertility market is experiencing growth due to the rising rates of infertility among couples in the US. Recent data indicates that approximately 10-15% of couples face difficulties in conceiving, which translates to millions of individuals seeking assistance. Factors contributing to this trend include delayed childbearing, lifestyle choices, and environmental influences. As more couples confront infertility, the demand for fertility treatments and services is likely to increase. This growing need for solutions is propelling the infertility market forward, as healthcare providers and fertility clinics expand their offerings to accommodate a larger patient base. The market is projected to reach a valuation of over $20 billion by 2026, highlighting the urgency and importance of addressing infertility issues in the US.

### Advancements in Fertility Treatments

Innovations in fertility treatments are significantly impacting the infertility market. Techniques such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and preimplantation genetic testing (PGT) have revolutionized the way infertility is treated. The introduction of new technologies and methodologies has improved success rates, making these treatments more accessible and effective. For instance, the success rate of IVF has increased to around 40% for women under 35, which encourages more couples to seek help. As these advancements continue to evolve, they are likely to attract a broader demographic, further driving the growth of the infertility market. The increasing availability of advanced reproductive technologies is expected to enhance patient outcomes and satisfaction, thereby solidifying the market's expansion.

### Increased Investment in Fertility Research

Investment in fertility research is playing a crucial role in shaping the infertility market. With a growing recognition of infertility as a public health issue, both public and private sectors are allocating more resources towards research and development. This influx of funding is facilitating the exploration of new treatments, understanding the underlying causes of infertility, and improving existing technologies. For instance, the National Institutes of Health (NIH) has increased its funding for reproductive health research, which is expected to yield innovative solutions in the coming years. As research continues to advance, it is likely to lead to breakthroughs that enhance treatment efficacy and patient care, thereby propelling the infertility market forward.

### Changing Demographics and Lifestyle Factors

Changing demographics and lifestyle factors are significantly influencing the infertility market. As societal norms evolve, individuals are increasingly prioritizing education and career advancement, often leading to delayed family planning. Additionally, lifestyle choices such as diet, exercise, and stress management are becoming more recognized as critical factors affecting fertility. The prevalence of conditions such as obesity and polycystic ovary syndrome (PCOS) is also contributing to infertility rates. As awareness of these issues grows, there is a corresponding increase in demand for fertility services and education. This shift in demographics and lifestyle is likely to continue shaping the infertility market, as healthcare providers adapt to meet the needs of a changing population.

### Growing Acceptance of Fertility Preservation

The growing acceptance of fertility preservation techniques is emerging as a key driver in the infertility market. As individuals become more aware of their reproductive options, particularly in the context of career planning and health concerns, the demand for egg and sperm freezing services is on the rise. This trend is particularly evident among women who wish to delay childbirth for personal or professional reasons. According to recent statistics, the number of women opting for egg freezing has increased by over 30% in the past few years. This shift in societal attitudes towards fertility preservation is likely to contribute to the expansion of the infertility market, as more individuals seek to safeguard their reproductive health for the future.

## Future Outlook

The [Infertility Market](https://www.marketresearchfuture.com/reports/infertility-market-6145) experiences a -0.1% CAGR from 2025 to 2035, driven by technological advancements, changing societal norms, and increasing awareness of reproductive health.

**New opportunities:**

- Development of [telehealth](https://www.marketresearchfuture.com/reports/telehealth-market-900)platforms for remote consultations Investment in AI-driven fertility tracking applications Expansion of fertility preservation services for aging populations

By 2035, the market is expected to stabilize, reflecting evolving consumer needs and technological integration.

## Segment Insights

### By Type: Assisted Reproductive Technology (Largest) vs. Hormone Therapy (Fastest-Growing)

The US infertility market is characterized by diverse treatment methodologies with Assisted Reproductive Technology (ART) commanding a significant market share. ART encompasses a range of techniques including in-vitro fertilization (IVF) which dominate due to high success rates and wide acceptance. Hormone Therapy, while smaller, is gaining traction as awareness of its benefits increases, especially in cases of hormonal imbalance contributing to infertility.

The growth trends within this segment indicate a robust increase in demand for innovative reproductive technologies and therapies. Factors driving this growth include advancements in medical technology, increasing societal acceptance of infertility treatments, and rising infertility rates. Additionally, the push for fertility preservation methods among young individuals fueled by lifestyle changes is likely contributing to the dynamic growth of Hormone Therapy.

Assisted Reproductive Technology: ART (Dominant) vs. Hormone Therapy (Emerging)

Assisted Reproductive Technology (ART) stands as the dominant approach in the US infertility market, characterized by high efficacy rates and a wide range of procedures such as IVF and ICSI. ART's extensive application in various infertility cases sets it apart as a preferred choice among practitioners and patients alike. Conversely, Hormone Therapy is considered an emerging segment, focusing on restoring hormonal balance to combat infertility and is particularly appealing to those not ready to pursue invasive procedures. Both segments provide crucial support to individuals facing infertility, but ART's proven success has led it to maintain a dominant position, while Hormone Therapy continues to grow as more individuals seek less invasive options.

### By End User: Fertility Clinics (Largest) vs. Hospitals (Fastest-Growing)

In the US infertility market, the end user segment demonstrates a diverse distribution with fertility clinics holding the largest share due to their specialized services and patient-centric approaches. Hospitals also play a significant role in this market, providing comprehensive care and treatment options, but they lag behind fertility clinics in terms of market share distribution. 

The growth trends within this segment are largely driven by increasing awareness of infertility issues and advancements in reproductive technologies. Fertility clinics are experiencing robust growth as they continue to adopt innovative treatment protocols, whereas hospitals are emerging as fast-growing alternatives, driven by their capacity to integrate infertility treatments within broader healthcare services and attract more patients seeking comprehensive solutions.

Fertility Clinics (Dominant) vs. Hospitals (Emerging)

Fertility clinics are at the forefront of the US infertility market, recognized for their innovative treatments and specialized care tailored to individual patient needs. Their dominance is attributed to their focused approach in addressing infertility challenges, combined with a range of services that include IVF, egg freezing, and hormonal therapies. Meanwhile, hospitals are gaining traction as an emerging player in this market, leveraging their established patient base and comprehensive healthcare offerings. They provide essential infertility services alongside other medical treatments, making them a convenient choice for patients. The evolving landscape emphasizes a synergy between clinics and hospitals to ensure patients receive holistic care, ultimately enhancing outcomes in the management of infertility.

### By Gender: Female (Largest) vs. Male (Fastest-Growing)

In the US infertility market, the gender segment showcases significant differences in market share distribution. The female segment holds the largest share due to traditional perceptions linking infertility more prevalently to women, alongside a range of female-specific treatments and therapies. In contrast, the male segment, although smaller, is witnessing steady growth as awareness of male infertility issues increases, prompting discussions around the importance of male health in infertility solutions.

Growth trends in the gender segment are driven by gradual shifts in societal attitudes towards infertility. Increased education and awareness are helping to destigmatize male infertility, leading to an upsurge in demand for male fertility treatments. Moreover, advancements in medical technology, such as sperm retrieval and assisted reproductive technologies, contribute to the male segment's rapid expansion, marking it as one of the fastest-growing areas in the US infertility market.

Female (Dominant) vs. Male (Emerging)

The female segment remains the dominant force in the US infertility market, attributed to a comprehensive array of treatment options specifically targeting female infertility issues, including medications and assisted reproductive technologies. This dominant position is reinforced by a higher visibility of women seeking fertility treatments. In contrast, the male segment is emerging as a vital area in the fertility landscape due to a growing recognition of male infertility, fueled by increased awareness campaigns and clinical research. While traditionally overshadowed, the male segment is rapidly evolving with cutting-edge advancements in fertility treatments, thus gaining traction and presenting new opportunities for market players specializing in male reproductive health.

### By Cause of Infertility: Ovulatory Disorders (Largest) vs. Male Factor Infertility (Fastest-Growing)

In the US infertility market, the landscape of causes for infertility reveals that ovulatory disorders account for a significant market share, making them the largest segment. This category encompasses a variety of reproductive issues, often linked to hormonal imbalances and lifestyle choices. Following this, male factor infertility has emerged as a substantial contributor, driven by increasing awareness and the evolving attitudes towards male reproductive health.

Recent trends indicate that while ovulatory disorders maintain their dominance, male factor infertility is experiencing rapid growth and gaining attention from healthcare providers and patients alike. The growing acceptance of assisted reproductive technologies and increased research into male infertility are key drivers. Furthermore, societal changes and awareness campaigns are focusing on men's health, leading to more diagnoses and treatments, thus amplifying this segment's growth potential.

Ovulatory Disorders: Dominant vs. Male Factor Infertility: Emerging

Ovulatory disorders are characterized by irregular ovulation patterns, making them a prevalent cause of infertility among women. This segment includes conditions such as polycystic ovary syndrome (PCOS) and hormonal imbalances that directly affect egg production. With increased recognition of these disorders, more women are seeking treatments, contributing to its dominant position in the market. Conversely, male factor infertility encompasses issues related to sperm quality and quantity, and is becoming increasingly prominent as societal norms evolve. Factors such as lifestyle changes, environmental influences, and growing health awareness play a crucial role in the assessment and treatment of male infertility. As knowledge and technology advances, both segments are expected to see continued engagement and proactive treatment options.

## Competitive Benchmarking

The infertility market exhibits a dynamic competitive landscape characterized by innovation and strategic partnerships. Key players such as CooperSurgical (US), Merck KGaA (DE), and Ferring Pharmaceuticals (CH) are actively shaping the market through various operational strategies. CooperSurgical (US) focuses on expanding its product portfolio, particularly in reproductive health technologies, while Merck KGaA (DE) emphasizes research and development to enhance its offerings in fertility treatments. Ferring Pharmaceuticals (CH) is strategically positioned through its commitment to personalized medicine, which aligns with the growing demand for tailored fertility solutions. Collectively, these strategies contribute to a competitive environment that prioritizes innovation and responsiveness to patient needs. The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of key players is substantial, as they leverage their resources and expertise to establish a competitive edge. This fragmentation allows for niche players to emerge, yet the dominance of established companies shapes the overall market dynamics. In October 2025, CooperSurgical (US) announced a strategic partnership with a leading biotechnology firm to develop next-generation fertility solutions. This collaboration is expected to enhance CooperSurgical's capabilities in genetic testing and embryo selection, potentially revolutionizing the IVF process. The strategic importance of this partnership lies in its potential to improve success rates in assisted reproductive technologies, thereby addressing a critical need in the market. In September 2025, Merck KGaA (DE) launched a new digital platform aimed at providing comprehensive support for patients undergoing fertility treatments. This initiative reflects a growing trend towards digitalization in healthcare, offering patients access to resources and information that can enhance their treatment experience. The strategic significance of this move is underscored by the increasing reliance on technology to facilitate patient engagement and improve outcomes. In August 2025, Ferring Pharmaceuticals (CH) expanded its product line with the introduction of a novel hormone therapy designed to optimize ovarian stimulation. This product launch is indicative of Ferring's commitment to innovation and its focus on addressing specific patient needs. The strategic importance of this development lies in its potential to enhance treatment efficacy and patient satisfaction, further solidifying Ferring's position in the market. As of November 2025, current competitive trends in the infertility market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative treatment options, and reliable supply chains. This shift underscores the importance of adaptability and forward-thinking strategies in maintaining a competitive edge in the rapidly evolving infertility market.

## Recent News & Developments

The US Infertility Market has recently seen significant developments, with a focus on advancements in reproductive technologies and treatments. Companies such as Boston IVF and HRC Fertility are at the forefront of innovation, utilizing cutting-edge techniques to enhance success rates in assisted reproductive technologies. In August 2023, Merck KGaA announced a partnership with UCSF Center for Reproductive Health aimed at increasing access to fertility preservation services. Additionally, Evoque is focusing on expanding its genetic screening capabilities, which is essential for improving patient outcomes.

The market is also witnessing growth due to rising infertility rates, influenced by lifestyle factors and increased awareness around reproductive health. In terms of mergers and acquisitions, in June 2023, Ferring Pharmaceuticals acquired a subsidiary of Vitrolife, further consolidating its position within the US market. The overall valuation of the US Infertility Market is projected to grow substantially, driven by advancements in technology and increasing demand for effective infertility treatments. Collaborations between companies such as AbbVie and Reproductive Health Technology highlight the ongoing efforts to enhance research and development in this field.

## Report Scope

| MARKET SIZE 2024 | 534.26(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 533.73(USD Million) |
| MARKET SIZE 2035 | 528.67(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | -0.1% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | CooperSurgical (US), Merck KGaA (DE), Ferring Pharmaceuticals (CH), Irvine Scientific (US), Vitrolife (SE), Reproductive Health Technologies (US), OvaScience (US), Genea (AU) |
| Segments Covered | Type, End User, Gender, Cause of Infertility |
| Key Market Opportunities | Advancements in personalized reproductive technologies enhance treatment efficacy in the infertility market. |
| Key Market Dynamics | Rising consumer demand for advanced reproductive technologies drives innovation and competition in the infertility market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall valuation of the US infertility market in 2024?**
A: The overall market valuation was $534.26 Million in 2024.

**Q: What is the projected market valuation for the US infertility market by 2035?**
A: The projected valuation for 2035 is $528.67 Million.

**Q: What is the expected CAGR for the US infertility market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is -0.1%.

**Q: Which segment had the highest valuation in the US infertility market in 2024?**
A: The segment of Assisted Reproductive Technology had the highest valuation at $250.0 Million in 2024.

**Q: How did the Fertility Preservation segment perform in 2024?**
A: The Fertility Preservation segment recorded a valuation of $104.26 Million in 2024.

**Q: What are the key players in the US infertility market?**
A: Key players include CooperSurgical, Merck KGaA, Ferring Pharmaceuticals, and others.

**Q: What was the valuation of the Home Care Settings segment in 2024?**
A: The Home Care Settings segment had a valuation of $84.26 Million in 2024.

**Q: How does the market valuation for Male Factor Infertility compare to Female infertility in 2024?**
A: In 2024, Male Factor Infertility was valued at $134.26 Million, while Female infertility was valued at $400.0 Million.

**Q: What was the valuation of the Fertility Clinics segment in 2024?**
A: The Fertility Clinics segment was valued at $250.0 Million in 2024.

**Q: Which cause of infertility had the highest valuation in 2024?**
A: Ovulatory Disorders had the highest valuation at $150.0 Million in 2024.

**Q: What is the estimated market size of the US Infertility Market in 2024 and 2035?**
A: The US Infertility Market is expected to be valued at 430 million USD in 2024 and projected to reach 1611 million USD by 2035.

**Q: Which segment of the US Infertility Market is anticipated to hold the largest share in 2024?**
A: In 2024, the Female segment is anticipated to hold the largest share at 186 million USD.

**Q: What are the projected market values for males, females, and unexplained infertility in 2035?**
A: By 2035, the market values are projected to be 486 million USD for males, 681 million USD for females, and 444 million USD for unexplained infertility.

**Q: Who are the key players in the US Infertility Market?**
A: Major players in the US Infertility Market include Boston IVF, Ferring Pharmaceuticals, Thermo Fisher Scientific, and Merck KGaA.

**Q: What opportunities and growth drivers are present in the US Infertility Market?**
A: Key growth drivers include advancements in reproductive technology and increasing awareness of infertility treatments.

**Q: How has the competitive landscape of the US Infertility Market evolved recently?**
A: The competitive landscape has evolved with increased partnerships and innovations among key players in the industry.

**Q: What potential challenges might the US Infertility Market face in coming years?**
A: Potential challenges may include regulatory hurdles and varying patient access to infertility treatments.

**Q: Which factors are expected to contribute to the growth of the US Infertility Market?**
A: Factors such as aging populations and lifestyle changes are expected to significantly contribute to market growth.

**Q: What regional trends are influencing the US Infertility Market?**
A: Regional trends are showing increased demand for fertility services in urban areas with high population concentrations.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-infertility-market-17960*